Clinical Trial Update: Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) [Phase 3]

View source ↗

Summary

This clinical trial update reports on antibody persistence and long-term safety data from a Phase 3 chikungunya vaccine study (VLA1553).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya Virus Infection

Drugs mentioned

• VLA1553

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Chikungunya Virus Infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING